Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience ...

Lumexa Imaging, formerly known as US Radiology Specialists, has filed with the SEC to go public and is set to raise as much ...

Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but as the company’s CEO sees it—it’s never about the price tag. | Novartis may have signed off on the second ...

Precise Bio has reported the first successful human implantation of its 3D-printed cornea implant, constructed of functional ...

As the biopharma world predominantly invests in late-stage assets, Eli Lilly is prioritizing early science with the opening ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors.  | Dexcom said Smart Basal is the ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

“Under Belgian rules, you can't really do that because it takes a 75% vote,” Gosebruch explained. “Gilead owns 25% and ...

Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...